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SAFETY CONSTRAINT OPTIMIZATION OF COMBINATION DRUG THERAPY IN 
HYPERTENSION CLINICAL TRIALS 
by 
VICTOR CHUKWU 
(Under the Direction of Karl Peace) 
ABSTRACT 
In Clinical Practice, combination drug therapy has become common in treating many disease 
conditions. The purpose of these combinations is often to ensure optimal efficacy and to reduce 
adverse effects that may arise from monotherapy. Clinical trials have also been conducted to 
ensure efficacy and safety of these combinations before they are introduced into the market. 
However, adverse effects still occur with combination therapies. The objective of this study is to 
(1) To determine a region of optimum doses of Drug A and Drug B in combination while
focusing on efficacy alone (2) To determine a region of optimum doses of Drug A and Drug B 
while focusing on efficacy incorporating important safety constraints. Using Hypertension as the 
disease of interest, the primary efficacy endpoint is the change in diastolic blood pressure from 
baseline to the end of treatment at 8 weeks, and the adverse effect is edema. Drug A in doses of 
0mg, 2.5mg, 5mg, 10mg and Drug B in doses of 0mg, 20mg, 40mg, 80mg were used in 
combination in the treatment of hypertension I and II. Response Surface Methodology (RSM) 
was used to find the doses of Drug A and Drug B which maximized efficacy, and a Probit-
Normal Model was used to model the probability of the occurrence of edema. Results showed an 
unconstrained optimal decrease of 21mmhg corresponding to 12mg of A and 48mg of B. The 
point of minimum risk of the probability of edema occurring coincided with 2.5mg of Drug A 
and 20mg of Drug B (0.006%). The region of minimal edema incidence lay around the 
combination of 2.5mg of Drug A and 20-40mg of Drug B. A combination of 10mg of Drug A 
and no dose of Drug B showed the highest probability of edema. At a desired target of zero 
probability of edema occurrence, the constrained optimal value was about 15mmhg. Response 
Surface Methodology (RSM) has been applied in many disciplines; constraint optimization 
methods are relatively novel in their application to health and clinical dosing. Application of this 
method will require formulation of constraints that are appropriate for the disease of interest, and 
that is also clinically appropriate. 
INDEX WORDS: Response surface experiments, Clinical trials, Combination drug therapy, 
Adverse effects, Optimization, Constraint optimization, Hypertension, Food and Drug 
Administration (FDA), World Health Organization (WHO), Public health.  
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CHAPTER 1 
INTRODUCTION 
A Clinical trial is a research study conducted to assess the utility of an intervention. 
Interventions can be biologics, drugs or devices, and can be preventive, diagnostic or therapeutic 
(Peace & Chen, 2010).  
Clinical trials are conducted in different phases; (i) human pharmacology study, (ii) 
therapeutic exploratory study (iii) therapeutic confirmatory study (iv) therapeutic use study or 
post marketing surveillance study (ICH, 1997). These are commonly known as Phase I, Phase II, 
Phase III and Phase IV, respectively. Though the objectives of each phase are clear, the 
processes during each phase are not restrictive. Phase I trials are usually conducted in healthy 
subjects. This phase identifies the safety range, a range of tolerable doses to avoid future severe 
adverse effects (Peace & Chen, 2010). The major objective is to estimate the “maximum dose 
level” – Maximum Tolerated dose (MTD) – “that is acceptable for a patient or participant 
without causing unacceptable toxicity” (Hee, 2012). This phase also assesses the absorption, 
distribution, metabolism and excretion of drugs. In cancer, “Virtually all existing phase I designs 
rely on toxicity while making the implicit assumption that higher doses are associated with 
higher response rates” (Thall & Russell, 1998).  
Phase II and III clinical trials are controlled. The effects of an experimental treatment and 
a control treatment are compared. The control treatment could be a placebo, or an “existing 
established effective treatment” (Fitzpatrick, 2005). Phase II clinical trials estimate the dose and 
frequency of dosing needed for designing the pivotal proof of efficacy trials. Phase II trials focus 
on the efficacy of the drug but are not usually designed with large power. Several dose levels and 
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frequencies of dosing of the new treatment are compared to a control or a known standard 
treatment. Phase III clinical trials are designed with large power to confirm the efficacy of the 
treatment regimen determined in Phase II (Peace & Chen, 2010). Phase III trials are normally 
conducted in many centers (multi-center trials), due to the requirement of large sample sizes. In 
addition to confirmation of efficacy, many Phase III trials collect longer term safety data (Peace 
& Chen, 2010). Phase IV clinical trials are conducted after the drug has been approved and 
registered and aim to assess safety and collect efficacy data in a more heterogeneous population.  
Hypertension 
Hypertension is an increase in blood pressure above normal levels. It affects about 75 
million Americans (32%), and only about half (54%) of those with this condition have it under 
control (CDC, 2016). The prevalence of hypertension has remained significantly unchanged 
despite the availability of numerous antihypertensive drugs. Hypertension is a risk factor for 
many cardiovascular diseases such as stroke, peripheral arterial disease, renal insufficiency, atrial 
fibrillation and dementia (Alberto Francisco, 2018). Several studies have shown that combined 
therapy is more effective in the treatment of hypertension. Combined therapy is advised for 
patients whose systolic pressure is 20mmHg above the target or diastolic pressure is 10mmHg 
above the target (Alberto Francisco, 2018). It has been demonstrated that combination therapy: 
(i) lowers the blood pressure more rapidly, (ii) encourages better adherence, (iii) has been
associated with better control of the blood pressure due to less titration of monotherapy and is 
(iv) less associated with adverse effects. There is ample evidence to show that outcomes are
better with combined therapy (Ahc, 2019). Though the use of combination therapy protects 
target organs against high dosage damages in monotherapy (Alberto Francisco, 2018), it is 
important to note that safety always places a constraint on efficacy (Peace & Chen, 2010). Drug 
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treatments are not always without side effects even with combination therapy. There is a risk for 
potential drug toxicity as the doses are increased to control blood pressure. In a recently 
concluded clinical trial, the combination of telmisartan and Ramipril have decreased glomerular 
filtration rate, increased serum creatinine and the risk of dialysis (Alberto Francisco, 2018). 
Research Objectives 
This research focuses on determining a region of doses of two drugs to be used in 
combination over which the efficacy of the combination is optimal (in some clinical sense) while 
constraining for safety (comparative effect of combination to control at an acceptable clinical 
level) in hypertensive patients. This may provide an alternative way to determine the dose levels 
for fixed combination drugs that may prove effective and safer in patients who require a fixed 
dose drug combination to treat their hypertension. Defining a region of efficacy while 
constraining for safety may lead to a reduction in side effects while successfully treating patients. 
Results from this research may enhance the establishment of a template where the method can be 
applied to a fixed dose combination in the treatment of other diseases. Our aim is:  
(1) To illustrate determining a region of optimum doses of two drugs given in combination
while focusing on efficacy alone, (RE) 
(2) To illustrate determining a region of optimum doses of two drugs while focusing on efficacy
and incorporating an important safety constraint (RE|s). 
Possible Research Outcomes 
(1) RE|s is a subset of RE; This will be a positive result, as the region of efficacy constraining for
safety has been defined and can be used for further consideration and studies. 
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(2) RE|s does not overlap with RE; then the efficacy of combination will need to be re-evaluated.
It may be that RE is a subset of RE|s. In this case, the method may need to be re-evaluated, or 
deemed not suitable. 
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CHAPTER 2 
LITERATURE REVIEW 
The maximum tolerated dose (MTD) is the highest dose with a clinically acceptable level 
of toxicity (Kong, Rai, & Bolli, 2014). Researchers have used various methods to find the dose 
of a treatment that meets both safety and efficacy requirements. This research proposes using 
response surface methods to simultaneously optimize the dose of a drug treatment, in the 
presence of safety constraints (adverse effects).  
Adverse Effects in Drug Therapy 
An adverse effect or reaction is “an appreciably harmful or unpleasant reaction, resulting 
from an intervention related to the use of a medicinal product, which predicts hazard from future 
administration and warrants prevention or specific treatment, or alteration of the dosage regimen, 
or withdrawal of the product” (Edwards & Aronson, 2000). These reactions can be classified into 
six types; Dose-related, non – dose related, dose – related and time – related, time – related, 
withdrawal and failure of therapy (Edwards & Aronson, 2000). Some of these effects can be 
unexpected, in which case not “consistent with domestic labelling” or expected from the known 
attributes of the drug. They could just be manifested during therapy without any causal link to 
the treatment, or could be serious, requiring hospital admission, prolonged hospital stay and 
resulting into disability or death (Edwards & Aronson, 2000). “Several studies carried out in the 
US have investigated adverse drug effects experienced by hospitalized patients and their impact 
on hospital costs. Patients who developed adverse effects were hospitalized an average of 1.2–
3.8 days longer than patients who did not, with additional hospital costs of $US2284–5640 per 
patient (2000 values)” (Rodríguez-Monguió, Otero, & Rovira, 2003). 
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Antihypertensives and Adverse Effects 
Croog et al conducted a multicenter randomized double-blind clinical trial among 
patients with hypertension. They showed that antihypertensive agents have several effects on the 
quality of life (Croog et al., 1986). A long-term surveillance study by Curb et al among 
hypertensive patients showed that 23.4% had “drug treatment discontinued due to possible side 
effects,” although only 1% of active participants required hospitalization (Curb et al., 1985). 
Table 1: Profile of Antihypertensives and Adverse Effects 
Class Examples Mechanism of Action Common Adverse Effects 
Alpha Blockers Terazosin, Doxazosin Blocks binding to alpha 
receptors to prevent 
contraction and 
narrowing of blood 
vessels 
Fatigue, Dizziness, Weight 
gain, hypotension, slow 
heart rate, shortness of 
breath  
Angiotensin – 
Converting 
Enzyme Inhibitors 
(ACEIs) 
Captopril, Lisinopril, 
Perindopril, Ramipril, 
Benazepril 
hydrochloride, Moexipril 
etc.  
Reduces blood pressure 
by inhibiting 
angiotensin (hormone) 
and preventing 
vasoconstriction.  
Fatigue, Headache, Cough, 
Hypotension, Increase in 
potassium blood levels 
Angiotensin II 
Receptor Blockers 
(ARBs) 
Azilsartan, Candesartan, 
Losartan, Telmisartan, 
Valsartan, Olmesartan 
Prevents angiotensin 
from binding to their 
receptors, thereby 
preventing 
Diarrhea, Cough, 
hypotension, Fatigue, 
Headache, Indigestion, etc. 
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vasoconstriction 
Beta – Blockers Atenolol, Carvedilol, 
Labetalol, Metoprolol, 
Nadolol, Bisoprolol etc. 
Reduces heart rate, and 
force of pressure, 
reduces blood volume 
Fatigue, Dizziness, 
Impotence, hypotension, 
shortness of breath, etc. 
Calcium channel 
blockers 
Amlodipine, Felodipine, 
Nifedipine, Nimodipine, 
Nicardipine, Verapamil, 
Clevidipine etc.  
Reduces muscular 
contractions in the heart 
by blocking the influx of 
calcium 
Edema, Rash, Headache, 
Constipation, Shortness of 
breath etc. 
Centrally acting 
drugs 
Clonidine, 
Hydrochloride, 
Guanfacine 
hydrochloride 
Works on the central 
nervous system to 
reduce blood pressure 
Low blood pressure, 
Withdrawal symptoms, 
Drowsiness, Headache etc. 
Diuretics Chlorothiazide, 
Ethacrynate, 
Bumetanide, Furosemide 
etc.   
Lowers blood volume, 
increases urination, 
reduces sodium 
Dehydration, Hypotension, 
Fatigue, hyperglycemia, 
increase level of uric acid. 
Etc. 
Renin Inhibitors Aliskiren Inhibits the conversion 
of angiotensinogen to 
angiotensin I 
Diarrhea, Increased 
potassium blood levels, etc. 
Vasodilators Minoxidill, Hydralazine Causes vasodilation of 
blood vessels thereby 
reducing blood pressure 
Edema, Weight gain, 
Increased heart rate, 
Headache etc.  
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Dosage Optimization in Combination Therapy 
Hatala et al, in a prospective, real-life, open-label, longitudinal, phase IV study optimized 
the treatment of blood pressure in patients with arterial hypertension with fixed-combination 
dosage of Perindopril/Amlodipine. Results showed marked reduction in systolic and diastolic 
blood pressure with reports of several side effects, the commonest of which was edema. 
However, there was notable reduction in the incidence of edema from 15% in patients treated 
with amlodipine at baseline to 7.9% after 1 months, and 6.3% after 3 months in patients treated 
with perindopril and amlodipine (Hatala, Pella, Hatalová, & Šidlo, 2012). Chen et al using 
pharmacokinetics/pharmacodynamic analysis and Monte-Carlo simulations optimized the dosage 
regimen of voriconazole to improve the efficacy in patients with invasive fungal disease (Chen et 
al., 2016). Optimization of Rituximab dosage in patients with non-Hodgkin’s lymphoma was 
found to be beneficial, using a validated pharmacokinetic/pharmacodynamic model but has yet to 
be confirmed in clinical trials (Ternant et al., 2012). Thall & Russell (1998) designed a single 
arm phase I/II trial, which included “dose-finding and simultaneous evaluation of safety and 
efficacy” (Thall & Russell, 1998). They were interested in generating decision rules using 
Bayesian criteria, calibrate the design parameters, and repeat the process until good operating 
characteristics were obtained (Thall & Russell, 1998).  
Constraint optimization of dosage in therapy may prevent suboptimal dosing in the 
treatment of serious health conditions. Physicians are careful in increasing doses among those 
with serious health conditions to avoid life threatening side effects. According to Niriayo et al, 
“medical practitioners may fail to prescribe high dose of Angiotensin Converting Enzyme 
Inhibitors (ACEIs) for older patients due to fear of intolerance,” and suboptimal dosage of 
ACEIs in patients with heart failure have resulted in increase in hospitalization (Niriayo, 
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Kumela, Gidey, & Angamo, 2019). In a cross-sectional study, binary logistic regression analysis 
was conducted to identify factors that affect utilization and optimal dosing of ACEIs (Niriayo et 
al., 2019). Optimizing ACEIs dosage in heart failure patients have proven to be have a better 
treatment outcome. “Evidence- based guidelines have recommended up titration of ACEIs to a 
target dose unless there is tolerability problem” (Niriayo et al., 2019). Further studies with 
constraint optimization will encourage adequate dosing in patients with less concerns over the 
side effects.  
Methods for Optimization 
“The problem of optimizing a quadratic primary-response function in the presence of a 
quadratic secondary-response function was considered by Myers and Carter” (1973). “ They also 
showed a special case of ridge analysis” (Stablein, Carter, & Wampler, 1983). Kong et al 
provided statistical methods for selecting the maximum effective dose and evaluating treatment 
effect when dose – response is monotonic (Kong et al., 2014). The methods proposed for a 
single-stage design and one two-stage design, require a prior assumption of a monotonic dose- 
response and a tested non-toxic dose range (Kong et al., 2014). Optimizing an optimal design 
with these methods can be “challenging yet interesting” (Kong et al., 2014). 
This research will use Response Surface Methodology (RSM) to find the optimum region 
of efficacy of Drug A and Drug B while simultaneously constraining for safety. Response 
surface models are general linear models in which attention focuses on characteristics of the 
fitted response function and in particular, where optimum estimated response values occur (SAS, 
2019). Response surface analysis is often “centered on the estimation of the levels of the design 
variables associated with the optimum response” (Stablein et al., 1983). “Response surface 
methodology is a kind of effective method to optimize process conditions, and it can determine 
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the influence of various factors and their interactions on the indices under investigation (response 
value) during technological operation. It can be used to fit a complete quadratic polynomial 
model through central composite experiment, and present more excellent experimental design 
and results expression” (H.Liu, 2016). RSM can also be used to generate “predicted values of 
changes from baseline for dose combinations not in the design” (H.Liu, 2016). It can also be 
used to study the additive property of  combination drugs, and the “nature of the dose response” 
(H.Liu, 2016). 
Constrained optimization has been applied in different areas ranging from mathematics, 
computer science, engineering and economics (Crown et al., 2017). “With advances in 
computing technology, constrained optimization methods designed to handle broader range of 
problems trace their origin to the development of the simplex algorithm – the most commonly 
used algorithm to solve linear constrained optimization problems” (Crown et al., 2017). It can 
also be useful in making clinical practice decisions where health professionals are faced with 
constraints such as proximity to treatment centers, health insurance benefits designs, and limited 
availability of health resources” (Crown et al., 2017). “These methods have been applied to 
disease diagnosis, development of optimal treatment algorithms, and the optimal design of 
clinical trials (Crown et al., 2017). There are various mathematical ways for solving 
maximization with constraints problems. These include the direct solution method, graphical 
method and the standard LaGrange multiplier method (Pernice, 2018). The LaGrange multiplier 
method, which was invented by an Italian mathematician Joseph-Louis LaGrange, is preferred 
more so than other methods because it can be generalized easily to many dimensions and many 
constraints (Pernice, 2018). “The method of Lagrange multipliers is used to solve constrained 
minimization problems of the following form: minimize Φ(x) subject to the constraint C(x) = 0” 
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(Menke & Menke, 2016). It should be noted that the method of maximum likelihood estimation 
usually minimizes the negative log likelihood. “The Lagrange multipliers indicate how much the 
value of the objective function at the optimal point will change for a small change in the right 
hand side of the constraint” (S.K.Jain & Singh, 2007). In ridge analysis, “Inserting values λ 
larger than the largest eigenvalue of the matrix B will result in a solution for the maximum 
response on the radius R. And inserting values of λ smaller than the smallest eigenvalue of the 
matrix B will result in a solution for the minimum response on the radius R” (Lawson, 2010). 
Myers and Carter (1973) advised on how to choose λ to ensure an “absolute optimum as opposed 
to a local one” (Stablein et al., 1983). 
Confidence Optimum region 
A confidence interval 100(1 − α)% can be constructed for the constrained optimum 
operating conditions for fixed λ. Computation of confidence regions for the maximum points is 
necessary to address sampling error problem (Del Castillo, 1996). 
According to Stablein et al., 1983, “it is more convenient to fix the value of each of the 
LaGrange multipliers, find the location of the constrained optimum, and then evaluate the 
constraints functions at the location of the optimum. If all of the constraints on the solution are 
satisfied then the solution is used. If not, the process is repeated with different values of  the 
LaGrange multiplier until an acceptable solution is found”. But this assumes that there is no 
closed form solution for the LaGrange multiplier. A better approach would be to apply the 
Karush-Kuhn-Tucker (KKT) method, where the LaGrange multplier can be obtained by fulfilling 
the necessary conditions for optimality (Del Castillo, 1996). 
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In a rotatable experimental design, (that is, the distance from the center to all points have 
equal prediction variance) and the 𝑉𝑉𝑉𝑉𝑉𝑉(𝑦𝑦�(𝑥𝑥)) is the only function of the distance between x and 
the center of the design region, √𝐱𝐱′𝐱𝐱, then we can find the stationary point using the Lagrangian 
function:   
𝐿𝐿 =  𝑏𝑏0 + 𝐱𝐱′𝐛𝐛 +  12 𝐱𝐱′𝐁𝐁𝐱𝐱 −  𝜇𝜇(x′x − 𝜌𝜌2)    (1)  
Where 𝜌𝜌 represents the radius of the experimental region, and 𝜇𝜇 is a Lagrange multiplier (Del 
Castillo, 1996). The KKT conditions would require that we maximize equation (1), subject to: 
𝜇𝜇(x′x − 𝜌𝜌2) = 0         (𝑉𝑉) 
𝜹𝜹 = 𝐛𝐛 + 𝐁𝐁𝐱𝐱 − 𝟐𝟐𝟐𝟐𝐱𝐱 = 0  (b) 
𝜇𝜇 ≥ 0   (c) 
Which produces x0 and the optimal value of 𝜇𝜇. Equation (a), (b) and (c) correspond to the KKT 
necessary conditions for optimality.  
According to Box and Hunter(1954), the “confidence region for a stationary point in the 
unconstrained case” is given by 𝜹𝜹′𝐕𝐕−𝟏𝟏𝜹𝜹 ≤ 𝑠𝑠2𝑘𝑘𝐹𝐹𝛼𝛼,𝑘𝑘,𝑛𝑛−𝑝𝑝  where 𝐕𝐕−𝟏𝟏 = 𝑬𝑬�𝜹𝜹𝜹𝜹′�𝝈𝝈𝟐𝟐 , s2 is the variance 
estimate based on n-p degrees of freedom, n denotes the number of experimental points, and p 
denotes the number of parameters. Box and Hunter (1957) also noted that the inequalty can be 
reduced to: 
𝜹𝜹′𝐕𝐕−𝟏𝟏𝜹𝜹 =  𝑛𝑛1 + 𝜆𝜆−1𝑐𝑐𝜌𝜌2 �𝜹𝜹′𝜹𝜹𝑐𝑐 −  𝑐𝑐𝑐𝑐1 + (𝜆𝜆−1 + 𝑐𝑐)𝑐𝑐𝜌𝜌2 (𝛿𝛿′𝑥𝑥)2�  ≤ 𝒌𝒌𝒔𝒔𝟐𝟐𝐹𝐹𝛼𝛼,𝑘𝑘,𝑛𝑛−𝑝𝑝 (2)
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Where 𝑐𝑐 = 𝑛𝑛
𝐹𝐹+2√𝐹𝐹
, F represents the number of factorial points, 𝑐𝑐 = 𝑘𝑘(𝝀𝝀−𝟏𝟏)+𝟐𝟐
𝝀𝝀�(𝑲𝑲+𝟏𝟏)𝝀𝝀−𝒌𝒌� and 𝜆𝜆 are the 
design parameters used to assess rotatablity. The confidence region is derived by substituing for 
𝜹𝜹 in equation (2). Any point that satisfies the equation (2) is inside the 100(1 − 𝛼𝛼)% confidence 
region for the constrained maximum point of the fitted response (Del Castillo, 1996). 
Dual Surface Response Approach 
This approach was first proposed by Myers and Carter in 1973, and was later developed 
by Vining and Myers in 1990 for two responses that can be categorized as primary and 
secondary responses (Lin & Tu, 1995). In this approach, second order models are fit to both a 
primary and secondary responses, and then an optimization of the primary response will be done 
subject to the secondary response.  
Following the notations Vining and Myers used the primary and secondary responses 
(respectively) can be written as: 
𝜂𝜂𝑐𝑐 =  𝛽𝛽0 +  �𝐵𝐵𝑖𝑖𝑥𝑥𝑖𝑖 + 𝑘𝑘
𝑖𝑖=1
�𝐵𝐵𝑖𝑖𝑖𝑖𝑥𝑥𝑖𝑖𝑖𝑖
2 +  ��𝛽𝛽𝑖𝑖𝑖𝑖𝑥𝑥𝑖𝑖𝑥𝑥𝑖𝑖 +  𝜀𝜀𝑐𝑐𝑘𝑘
𝑖𝑖<𝑖𝑖
𝑘𝑘
𝑖𝑖=1
 
𝜂𝜂𝑝𝑝 =  𝛾𝛾0 +  �𝛾𝛾𝑖𝑖𝑥𝑥𝑖𝑖 + 𝑘𝑘
𝑖𝑖=1
�𝛾𝛾𝑖𝑖𝑖𝑖𝑥𝑥𝑖𝑖
2 +  ��𝛾𝛾𝑖𝑖𝑖𝑖𝑥𝑥𝑖𝑖𝑥𝑥𝑖𝑖 +  𝜀𝜀𝑝𝑝𝑘𝑘
𝑖𝑖<𝑖𝑖
𝑘𝑘
𝑖𝑖=1
 
And the fitted response surfaces resulting from the equations above can be represented by: 
𝑤𝑤�𝑐𝑐 = 𝑏𝑏0 + 𝐱𝐱′𝐛𝐛 + 𝐱𝐱′𝐁𝐁𝐱𝐱 
𝑤𝑤�𝑝𝑝 = 𝑐𝑐0 + 𝐱𝐱′𝐜𝐜 + 𝐱𝐱′𝐂𝐂𝐱𝐱 
where 𝑏𝑏0 =  ?̂?𝛽0, 𝑐𝑐0 =  𝛾𝛾�0,𝐛𝐛 = �?̂?𝛽1, … , ?̂?𝛽𝑘𝑘�′, 𝐜𝐜 =  (𝛾𝛾�1, … ,𝛾𝛾�𝑘𝑘)′,
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𝐁𝐁 =  12
⎣
⎢
⎢
⎡2?̂?𝛽11 ?̂?𝛽12 … ?̂?𝛽1𝑘𝑘
?̂?𝛽12 2?̂?𝛽22 ⋯ ?̂?𝛽2𝑘𝑘
⋮ … ⋱ ⋮
?̂?𝛽1𝑘𝑘 ?̂?𝛽2𝑘𝑘 ⋯ 2?̂?𝛽𝑘𝑘𝑘𝑘⎦⎥⎥
⎤
 
𝐂𝐂 =  1
2
�
2𝛾𝛾11 𝛾𝛾�12 … 𝛾𝛾�1𝑘𝑘
𝛾𝛾�12 2𝛾𝛾�22 ⋯ 𝛾𝛾�2𝑘𝑘
⋮ … ⋱ ⋮
𝛾𝛾�1𝑘𝑘 𝛾𝛾�2𝑘𝑘 ⋯ 2𝛾𝛾�𝑘𝑘𝑘𝑘� 
Where 𝑏𝑏0, 𝑐𝑐0,𝐛𝐛, 𝐜𝐜,𝐁𝐁, and 𝐂𝐂 are the appropriate vectors and matrices of the estimates for the 
coefficients. 
Vining and Myers proposed a method using LaGrange multipliers, for finding x that 
optimizes 𝑤𝑤�𝑐𝑐 subject to 𝑤𝑤�𝑝𝑝 = T, “where T is some desired target value of the constraint response 
and a spherical region of interest is assumed” (2). The goal is to find x that satisfies: 
𝜕𝜕𝐿𝐿
𝜕𝜕𝐱𝐱
= 0 
Where, 
𝐿𝐿 =  𝑏𝑏0 + 𝐱𝐱′𝐛𝐛 + 𝐱𝐱′𝐁𝐁𝐱𝐱 +  λ(𝑐𝑐0 + 𝐱𝐱′𝐜𝐜 + 𝐱𝐱′𝐂𝐂𝐱𝐱 − T) 
The DMRCS Steps for Optimization 
Myers et al proposed five steps that can help organize the optimization process, and 
enhance a “structured decision that is defensible and rational” (Myers, Montgomery, & 
Anderson-Cook, 2016). The steps which have been abbreviated by DMRCS are: Define, 
Measure, Reduce, Combine and Select.  
Define. This step clearly lays out the objective of the optimization process. The problem 
to be solved, responses to be considered, factors involved in the design, and constraint ranges (if 
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present) are all noted and clearly defined (Myers et al., 2016). This step makes sure that the 
“correct problem is solved”. In multiple responses optimization, care is taken to ensure that 
“decisions are represented with an appropriate response (Myers et al., 2016). 
Measure. This step ensures that the data used for the analysis is of high quality. 
Decisions based on the results of the optimization need to be “precisely and accurately measured 
to allow fair and consistent comparisons between potential solutions” (Myers et al., 2016).  
Reduce. It is important that too many responses are not to be included in the optimization 
process, as the “trade-offs between responses increases as the number of facets considered 
increases” (Myers et al., 2016). Another form of reduction is to “eliminate noncontending 
solutions” from the optimization considerations.  
Combine. Several methods can be used to combine different metrics into a form where 
they can be easily compared. Tools such as “overlaying contours, constrained optimization, or 
the desirability function approach with specific weights provide ways of eliminating portions of 
the design space” help to make relevant conclusions from the optimization processes.  
Select. The goal of the optimization process is to select a region of the optimized space 
that meets the objectives of the study. Graphical tools play a big role in visualizing and 
explaining results.  
Using this structured approach can enhance the smoothness of implementation, and the quality of 
results obtained (Myers et al., 2016). 
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CHAPTER 3 
METHODOLOGY 
Data was generated to follow a study sponsored by a pharmaceutical organization 
(NCT00281580, 2014). The study was a factorial design study for the treatment of Hypertension 
I and II. The Primary outcome was change from baseline at 8 weeks in Seated Trough Cuff Mean 
Diastolic Blood Pressure (DBP). Secondary outcome was change from baseline at 8 weeks in 
Seated Trough Cuff Mean Systolic Blood Pressure. Drug A in doses of 0mg, 2.5mg, 5mg, and 
10mg was given in combination with Drug B, in doses of 0mg, 20mg, 40mg and 80mg, for eight 
weeks in patients with Hypertension stage I and II. The simstudy package in R software was 
used to generate the data (Goldfeld, 2019). A total of 8000 observations were generated, 500 
observations in each treatment group, with the following variables; identity number, dose of 
Drug A, dose of Drug B, Baseline Diastolic Blood Pressure, End of Treatment Diastolic Blood 
Pressure, Age, Gender, Edema and Headache. Baseline Diastolic Blood Pressure (DBP) was 
generated to reflect a population like the study; i.e. those with hypertension I and II (that is, DBP 
of ≥ 95 and ≤ 119), with an age range of 18 – 75 years. Gender distribution of 52% males, and 
48% females in each treatment group, coded 1 for male and 2 for female. Table 2 shows the 
mean and the standard deviation for each treatment group used to generate the baseline diastolic 
blood pressure and the post baseline diastolic blood pressure (NCT00281580, 2014).  
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Table 2: Parameters used for generating Data for the baseline and end of treatment diastolic 
blood pressure 
Group Dose of Drug A 
& Drug B 
N Mean (SD) for 
Baseline DP 
Mean (SD) for 
Post Baseline DP 
1 B0A0 500 107 (9.4) 101(9.4) 
2 B20A0 500 107 (9) 94 (9) 
3 B40A0 500 107 (10.1) 94 (10.1) 
4 B80A0 500 107 (8.7) 93 (8.7) 
5 B0A2.5 500 107 (9.9) 96 (9.9) 
6 B0A5 500 107 (7.9) 94 (7.9) 
7 B0A10 500 107 (7.1) 90 (7.1) 
8 B20A2.5 500 107 (7.8) 89 (7.1) 
9 B20A5 500 107 (6.5) 92 (6.5) 
10 B20A10 500 107 (7) 88 (7) 
11 B40A2.5 500 107 (8.2) 90 (8.2) 
12 B40A5 500 107 (7.6) 90 (7.6) 
13 B40A10 500 107 (7.9) 87 (7.9) 
14 B80A2.5 500 107 (7.5) 91 (7.5) 
15 B80A5 500 107 (8.5) 89 (8.5) 
16 B80A10 500 107 (7.9) 87 (7.9) 
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Table 3 shows summary results by treatment group combination: the mean of baseline 
diastolic blood pressure, mean of end of treatment diastolic blood pressure, mean of change in 
diastolic blood pressure, and their corresponding standard deviations.  These results were 
produced using proc means in SAS.  
Table 3: Summary of Generated Data 
Group Dose of 
Drug A & 
Drug B 
N Mean Baseline 
DBP (SD) 
Mean End of 
Treatment DBP 
(SD) 
Mean change in DBP 
(SD) 
1 B0A0 500 106.95 (8.04) 101.01 (7.68) 5.94 (4.38) 
2 B20A0 500 106.86 (7.98) 94.10 (7.90) 12.99 (4.36) 
3 B40A0 500 107.12 (7.84) 93.99 (7.76) 13.13 (4.67) 
4 B80A0 500 107.02 (7.85) 92.99 (7.92) 14.02 (4.18) 
5 B0A2.5 500 106.85 (7.88) 96.03 (7.99) 10.82 (4.46) 
6 B0A5 500 106.80 (7.55) 93.91 (7.62) 12.90 (4.06) 
7 B0A10 500 106.89 (7.58) 89.99 (7.58) 16. 89 (3.74)
8 B20A2.5 500 107.09 (8.06) 88.59 (7.73) 18.50 (4.22) 
9 B20A5 500 106.92 (7.83) 92.07 (7.27) 14.85 (10.91) 
10 B20A10 500 106.91 (7.59) 88.02 (7.74) 18.90 (3.81) 
11 B40A2.5 500 107.20 (7.74) 90.09 (7.89) 17.11 (3.92) 
12 B40A5 500 107.14 (7.86) 90.10 (7.72) 17.04 (4.05) 
13 B40A10 500 107.14 (7.6) 86.93 (7.61) 20.20 (3.95) 
14 B80A2.5 500 106.77 (7.81) 91.14 (8.03) 15.66 (4.10) 
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15 B80A5 500 106.87 (7.57) 89.16 (7.74) 17.71 (4.03) 
16 B80A10 500 107.15 (7.55) 87.22 (7.64) 19.93 (4.11) 
This dissertation uses generated diastolic blood pressure data and real adverse event 
summary data of patients from the clinical trial (NCT00281580, 2014). Therefore, we compared 
the means of the generated diastolic blood pressure data to the means of the actual diastolic 
blood pressure data from the clinical trial (NCT00281580, 2014). Figures 1 and 2 are plots 
comparing the mean blood pressure (baseline and post-baseline) from the original study with the 
mean blood pressure (baseline and post-baseline) in the generated data.  
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Figure 1: A Plot Comparing Baseline Mean Diastolic Blood Pressure 
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Figure 2: A Plot Comparing Post-Baseline Mean Diastolic Blood Pressure 
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Table 4 shows the number and percentages of edema (side effect) per treatment group at risk as 
provided by the study (NCT00281580, 2014).  
Table 4: Number and percentages of edema (side effect) per 
treatment group at risk 
Treatment Group Peripheral Edema (%) 
Placebo (B0A0) 0/46 (0) 
B20A0 0/42 (0) 
B40A0 1/130 (0.77) 
B80A0 1/135 (0.74) 
B0A2.5 1/50 (2) 
B0A5 1/140 (0.71) 
B0A10 23/129 (17.83) 
B20A2.5 1/44 (2.27) 
B20A5 2/46 (4.35) 
B20A10 5/44 (11.36) 
B40A2.5 0/47 (0) 
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B40A5 2/143 (1.40) 
B40A10 7/129 (5.43) 
B80A2.5 1/48 (2.08) 
B80A5 3/146 (2.05) 
B80A10 16/142 (11.27) 
The objective is to determine the optimum combination of doses and corresponding 
confidence interval in a combined therapy of hypertension using drugs, Drug A and Drug B, in 
the presence of a constraint; on edema (a common side effect).  
Methods & Data Analysis. 
The first approach was to perform a response surface procedure to obtain the 
unconstrained optimum region or point of efficacy.  
In response surface experiments, the relationship between the dependent and the independent 
variables, x, is often expressed by a quadratic function (Lawson, 2010):  
 𝑓𝑓(𝑥𝑥) = 𝛽𝛽0 + 𝒙𝒙′𝜷𝜷 + 𝒙𝒙′𝚩𝚩𝒙𝒙  (3) 
Where; 
𝒙𝒙 =  �𝑥𝑥1𝑥𝑥2⋮
𝑥𝑥𝑘𝑘
� ,  𝛃𝛃 =  �β1β2
⋮
β𝑘𝑘
� ,   𝚩𝚩 =  
⎣
⎢
⎢
⎢
⎡
β(11) 12β(12) ⋯ 12β(1𝑘𝑘)
1
2
β(12) β(22) ⋯ 12β(2𝑘𝑘)
⋮ ⋮ ⋱ ⋮
1
2
β(1𝑘𝑘) 12β(2𝑘𝑘) ⋯ β(𝑘𝑘𝑘𝑘)⎦⎥
⎥
⎥
⎤ 
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β0 is the intercept, x is a vector of design variables, β is the vector of the coefficients of the linear 
terms in f(x) and B is a symmetric matrix containing functions of the coefficients of the quadratic 
terms in f(x).  
Let Yi be the dependent variable; the change in diastolic blood pressure, and 𝜖𝜖𝑖𝑖 are the 
independent error terms which follow independent and identical normal distributions with mean 
0 and equal variance 𝜎𝜎2. Then 𝑌𝑌𝑖𝑖 = 𝑓𝑓(𝑥𝑥) +  𝜖𝜖𝑖𝑖 and 𝑌𝑌𝑖𝑖 ~ 𝑁𝑁[𝑓𝑓(𝑥𝑥),𝜎𝜎2] 
The likelihood function could then be expressed as: 
𝐿𝐿(𝑌𝑌𝑖𝑖) =  �𝑃𝑃(𝑌𝑌𝑖𝑖)𝑘𝑘
𝑖𝑖=1
 
Where 𝑃𝑃(𝑌𝑌𝑖𝑖) is the normal density of  𝑌𝑌𝑖𝑖 which has mean f(x) and variance 𝜎𝜎2. 
ln 𝐿𝐿(𝑌𝑌𝑖𝑖) =  � ln𝑃𝑃(𝑌𝑌𝑖𝑖)𝑘𝑘
𝑖𝑖=1
 
=  �𝜀𝜀𝑖𝑖2𝑘𝑘
𝑖𝑖=1
 
=  ��𝑦𝑦𝑖𝑖 −  𝛽𝛽0 −  �𝛽𝛽𝑖𝑖𝑥𝑥𝑖𝑖𝑖𝑖𝑘𝑘
𝑖𝑖=1
�
2
𝑘𝑘
𝑖𝑖=1
 (4) 
The optimum response of the response surface methodology occurs at the stationary 
point. The stationary point can be expressed as:  
𝐱𝐱𝐩𝐩 =  − 12𝐁𝐁�−𝟏𝟏𝐛𝐛
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which is derived by setting the derivative of equation (4) to 0.  
The predicted response at the stationary point can be expressed as: 
𝑦𝑦�𝑝𝑝 =  𝑏𝑏0 +  𝐱𝐱′𝐩𝐩𝐛𝐛 +  𝐱𝐱′𝐩𝐩𝐁𝐁�𝐱𝐱𝐩𝐩 
=  𝑏𝑏0 +  𝐱𝐱′𝐩𝐩𝐛𝐛 + �−𝟏𝟏𝟐𝟐 𝐛𝐛′𝐁𝐁�−𝟏𝟏�𝐁𝐁�𝐱𝐱𝐩𝐩 
= 𝑏𝑏0 +  12 𝐱𝐱′𝒑𝒑𝐛𝐛 
The quadratic equation (3) can illustrate a variety of surfaces, such as ridges, hilltops, 
valleys and saddle points (Lawson, 2010). Whether f(x) is a minimum or maximum is determined 
by the eigenvalues of the 𝐁𝐁� matrix. If the eigenvalues are positive, it is a maximum. If negative, 
the point is a minimum. And if the signs are mixed (positive and negative), then the stationary 
point would be a saddle point. 
In order to fit the response surface model in SAS, one would need to employ the use of 
the SAS Response Surface Regression Procedure (RSREG). To better understand the fitted 
surface, a contour plot or a three-dimensional plot can be made. In the case of more than one or 
more contour plots, it is useful to perform a canonical analysis, where the exact factor 
coordinates of the optima can be determined. These can be determined by setting the derivates of 
the equation which have been fitted to zero and finding the solutions (Lawson, 2010). 
Data Analysis was done using SAS 9.4. The RSREG procedure was used to find the 
optimum response region assuming a full quadratic response function. According to SAS, Proc 
RSREG can also be used to test for lack of fit, test for the significance of individual factors, 
analyze the canonical structure of the estimated response surface, compute the ridge of optimum 
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response and predict new values of the response. The independent variables are the doses of 
Drug A and B in combination therapy. The dependent variable is the change in Diastolic Blood 
Pressure (DBP) from baseline to end of treatment after 8 weeks. The estimates of betas (𝛽𝛽0,𝛽𝛽1,𝛽𝛽2,𝛽𝛽11 ,𝛽𝛽12,𝛽𝛽22) in the full quadratic model were obtained from fitting the regression 
model using SAS PROC RSREG:  
𝑦𝑦 = 𝛽𝛽0 + 𝛽𝛽1𝑥𝑥1 + 𝛽𝛽2𝑥𝑥2 + 𝛽𝛽11𝑥𝑥12 + 𝛽𝛽22𝑥𝑥22 + 𝛽𝛽12𝑥𝑥1𝑥𝑥2 +  ε   
Where y = the change in diastolic blood pressure  
x1 = doses of Drug A 
x2 = doses of Drug B 
This assumes that the experimental errors are independent, normally distributed and have equal 
variances.  
The aim is to fit the model to the data, estimate parameters in the model, produce the 
estimated Response Surface, and then find the values (perhaps a region) of dose variables for 
which fitted model is optimum for some predicted response deemed clinical important. 
The adverse effect (edema) was also modeled to have an idea of the region that produces 
the highest probability of the occurrence of edema, in relation to the dose of Drug A and Drug B. 
The presence of edema variable was coded as a binary variable (1 or 0) for each patient. The 
presence of edema represented as 1 and 0 otherwise.  This kind of data is known as the quantal 
data, as it describes the “relationship between dose and the frequency of a particular outcome in 
a given population” (World Health Organization, 2019b). Various models such as One-hit, 
Gamma multi hit, Probit normal, and logistic, can be used on this type of data, depending on the 
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distribution (World Health Organization, 2019b). Proc Logistic in SAS, with a Probit normal link 
function, was used to produce predicted probabilities of edema occurrence at various dosage 
combinations of Drug A and Drug B. The equation for the model is given as: 
𝑃𝑃 [𝑌𝑌 = 1] =  Φ(𝛽𝛽0 + 𝛽𝛽1𝑥𝑥1 + 𝛽𝛽2𝑥𝑥2 + 𝛽𝛽11𝑥𝑥12 + 𝛽𝛽22𝑥𝑥22 + 𝛽𝛽12𝑥𝑥1𝑥𝑥2) 
where: 
Y = edema Status (1 or 0) 
x1 = doses of Drug A 
x2 = doses of Drug B 
According to Myers et al, “a relatively straightforward approach to optimizing several 
responses that works well when there are only a few variables is to overlay the contour plots” 
(Myers et al., 2016). This can help the experimenter to “visually examine the contour plot for 
determining appropriate operating conditions and select a region that is most desirable given 
other practical conditions” (Myers et al., 2016). The Response Surface Regression (RSREG) 
Procedure was used to overlay the contour plots of both the change in diastolic blood pressure, 
and the probability of edema occurrence. The overlaid contours can easily show that region of 
efficacy at a minimal risk of edema occurring. Different levels of efficacy can be visualized at 
several probability levels of edema occurring, based on the dose of Drug A and Dose B.  
Another method of optimization is the Constrained Optimization. “Constrained 
Optimization is a set of methods designed to efficiently and systematically find the best solution 
to a problem characterized by a number of potential solutions in the presence of identified 
constraints” (Crown et al., 2017). To achieve this, an objective function is maximized or 
minimized. The objective function represents the “measure of interest to the decision maker 
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which is subject to constraints that restrict the decision maker’s freedom of action” (Crown et al., 
2017). A constrained optimization problem is made up of the objective function(s), decision 
variable(s) and its constraint(s) (Crown et al., 2017). 
“The Objective function is the function of the decision variables which needs to be 
maximized or minimized. The decision variables are mathematical representation of the 
constituents of the system for which decisions are being taken to improve the value of the 
objective function value of the objective function. The constraints are the restrictions placed on 
the decision variables” (Crown et al., 2017). 
 The objective of the constrained optimization is to maximize f (x, y) given a constraint 
function; g (x, y) ≥ 0. In this study we maximized the objective function: 
𝑦𝑦 = 𝛽𝛽0 + 𝛽𝛽1𝑥𝑥1 + 𝛽𝛽2𝑥𝑥2 + 𝛽𝛽11𝑥𝑥12 + 𝛽𝛽22𝑥𝑥22 + 𝛽𝛽12𝑥𝑥1𝑥𝑥2 +  ε 
Subject to: 
Φ(𝛽𝛽0 + 𝛽𝛽1𝑥𝑥1 + 𝛽𝛽2𝑥𝑥2 + 𝛽𝛽11𝑥𝑥12 + 𝛽𝛽22𝑥𝑥22 + 𝛽𝛽12𝑥𝑥1𝑥𝑥2) ≤ desired target probability of 
edema occurrence. 
This assumes that the experimental errors (ε) are independent, normally distributed and have 
equal variances. 
The RSREG procedure in SAS for searching multiple response conditions was used to 
perform the constrained optimization, using different target probability of edema occurrence, and 
finding constrained optimal values. 
35 
CHAPTER 4 
RESULTS 
The Response Surface Methodology (RSM) was performed using Response Surface 
Regression (RSREG) Procedure in SAS. The unconstrained total model was statistically 
significant at 0.05 significant level (<0.001). As shown in Table 5, the predicted change in 
baseline diastolic pressure increases as the dose of Drug A and/or Drug B increase respectively. 
The lack of fit also revealed a significant result, as expected due to the large sample size and an 
R-square of 38.4%.
Table 5: ANOVA Summary, RSM Analysis 
Response 
Mean 
15.437 
Root MSE 4.217 
R-Square 0.3838 
CV 27.32 
Regression DF Type I SS R-Square F value Prob 
Linear 2 71507 0.2442 1409.67 <.0001 
Quadratic 2 17148 0.0586 338.05 <.0001 
Cross Product 1 1392.04 0.0048 54.88 <.0001 
Total Regress 5 90047 0.3075 710.06 <.0001 
Residual DF SS MS F value Prob 
Lack of fit 10 14680 1468.04 62.32 <.0001 
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Pure error 7984 188073 23.57 
Total error 7994 202753 25.36 
Parameter DF Estimate SD T value Prob 
Intercept 1 7.827 0.1623 48.24 <.0001 
X1 (Dose B) 1 0.2327 0.0072 32.28 <.0001 
X2 (Dose A) 1 1.2627 0.0577 21.91 <.0001 
X1*X1 1 -0.001950 0.00007940 -24.56 <.0001 
X1*X2 1 -0.003814 0.000515 -7.41 <.0001 
X2*X2 1 -0.043344 0.005082 -8.53 <.0001 
Factor DF SS MS F Prob 
X1 3 37439 12480 492.04 <.0001 
X2 3 54000 18000 709.69 <.0001 
Results also showed a stationary maximum point, with a predicted value at 21.24mmhg. 
Figure 1 and Figure 2 represents the contour plots and the surface graph respectively. Both 
figures show different values of the change in diastolic blood pressure at different combinations 
of Drug A and Drug B. From the contour plots and surface graph, one can deduce that the 
optimal point of efficacy is a change (reduction) in diastolic blood pressure from baseline to 8 
weeks of about 21mmhg. This optimal point of efficacy was associated with about 12mg of Drug 
A and 48mg of Drug B (which is close to marketed 10mg of Drug A and 40mg of Drug B). 
Table 6 shows the treatment groups, and the corresponding predicted change in diastolic blood 
pressure, with their confidence intervals.  
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Table 6: Values of predicted change in diastolic pressure with confidence Intervals 
Group Dose A Dose B Predicted 
Change in DBP 
(mmHg) 
Confidence 
Interval (mmHg) 
1 0 0 7.82 (-2.05, 17.70) 
2 0 20 11.70 (1.83, 21.58) 
3 0 40 14.02 (4.14, 23.89) 
4 0 80 13.96 (4.08, 23.84) 
5 2.5 0 10.71 (0.84, 20.59) 
6 5 0 13.06 (3.19, 22.93) 
7 10 0 16.13 (6.25, 26.01) 
8 2.5 20 14.40 (4.53, 24.27) 
9 5 20 16.55 (6.68, 26.43) 
10 10 20 19.24 (9.57, 29.12) 
11 2.5 40 16.52 (6.65, 26.40) 
12 5 40 18.48 (8.61, 28.36) 
13 10 40 20.79 (10.92, 30.66) 
14 2.5 80 16.08 (6.21, 25.96) 
15 5 80 17.67 (7.79, 27.54) 
16 10 80 19.42 (13.24, 25.59) 
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Figure 3: Response Contour Plot for the Change in Diastolic Blood Pressure. 
Figure 4: Response Surface Graph for Change in Diastolic Blood Pressure. 
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Table 7 summarizes results from the Probit Model for the probability of edema 
occurrence by the dose combinations of Drug A and Drug B. Results showed that a one unit (mg) 
change in the dose of Drug A increases the probability of edema status by 0.11%, a one unit (mg) 
change in the dose of Drug B decreases the probability of edema status by 0.0159%, and a one 
unit (mg) change in the combination of Drug A and B decreases the probability of edema by 
0.00024%.  
Table 7: Probit Model Summary Results 
Parameter DF Estimate Standard 
Error 
Wald 
Chi-Square 
Pr > ChiSq 
Intercept 1 -2.3912 0.1195 400.69 <.0001 
DoseA 1 0.1099 0.0424 7.4662 0.0063 
DoseB 1 -0.0159 0.00387 16.9421 <.0001 
DoseA*DoseB 1 -0.00024 0.000252 0.9043 0.3416 
DoseA*DoseA 1 0.00297 0.00322 0.8538 0.3555 
DoseB*DoseB 1 0.000194 0.000041 22.6960 <.0001 
Table 8 shows a summary of results from the probit normal model, showing the predicted 
probability of edema per dose combination, the difference in predicted probabilities (subtracted 
from probability of edema when its placebo) and the predicted optimal value of change in blood 
pressure. The point of minimum risk is at dose of Drug A 2.5mg and Drug B 40mg (if 
considering the combination). The region of minimal edema incidence lies around dosage 
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combination of Drug A 2.5mg and Drug B 20 – 40mg. The probability of edema reduces as the 
dosage of Drug B increases in the combination with Drug A.  
Table 8: Summary Results from Probit Regression showing Predicted Probability of Edema, 
difference from Placebo and the Predicted Change in Diastolic Pressure (CDBP) Optimal 
Value.  
Group Dose of 
Drug A 
& Drug 
B 
Predicted Prob of 
Event (Edema) 
Difference of Predicted 
Prob (from Placebo) 
Predicted Value 
(mmHg) from RSREG 
1 B0A0 0.0083(0.83%) 7.82 
2 B20A0 0.0042(0.42%) -0.004 11.70 
3 B40A0 0.0033(0.33%) -0.005 14.02 
4 B80A0 0.0076 (0.76%) -0.0007 13.96 
5 B0A2.5 0.018 (1.8%) 0.0097 10.71 
6 B0A5 0.039 (3.9%) 0.031 13.06 
7 B0A10 0.159 (15.9%) 0.151 16.13 
8 B20A2.5 0.009 (0.9%) 0.0007 14.40 
9 B20A5 0.021 (2.1%) 0.0127 16.55 
10 B20A10 0.109 (10.9%) 0.1007 19.24 
11 B40A2.5 0.0072 (0.7%) -0.0011 16.52 
12 B40A5 0.016 (1.6%) 0.0077 18.48 
13 B40A10 0.078 (7.8%) 0.0697 20.79 
14 B80A2.5 0.015 (1.5%) 0.0067 16.08 
15 B80A5 0.029 (2.9%) 0.0207 17.67 
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16 B80A10 0.111 (11.1%) 0.1027 19.42 
Figure 5 shows the response surface plot showing the highest probability of edema at 
15.3%, associated with Drug A 10mg and Drug B 0mg.  It is important to note that the 
probability reduced by 5% (10.9%) when Drug B 20mg was added to the combination.  
Figure 5: A Surface Plot showing the Probability of Edema occurrence by Doses. 
An overlaid contour plot is a good way of visualizing both responses and selecting a 
region of interest e.g. where the probability of edema is lowest. Figure 4 is an overlaid contour 
plot showing the estimated probabilities of edema occurring at different doses of Drug A and 
Drug B combinations. One can visually observe that the region of zero probability of edema 
occurring is around 2.5mg of Drug A and 20 – 40mg of Drug B, and slightly above a change in 
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diastolic blood pressure of 15mmHg. There will be a 20mmHg efficacy achieved with 10mg of 
Drug A and 50mg of Drug B, but with a 10% predicted probability of edema occurrence.  
Figure 6: An Overlaid Contour Plot for the Change in Diastolic Blood Pressure and the 
Probability of Edema Occurrence, at different combinations of Drug A and Drug B.  
Further analysis involved finding the constrained optimal point of efficacy at different 
targets of predicted probability. Table 9 shows results for respective dosage combinations of 
Drug A and Drug B at different levels of predicted probability of edema.  
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Table 9: Sensitivity Analysis showing respective dosage combinations at different targets of 
predicted probability of edema 
Target Probability of 
Edema Incidence (t) 
DoseA DoseB CDBP Optimal Value 
0% < t ≤ 1% 4 56 18.25 
1% < t ≤ 2% 5 55 18.91 
2% < t ≤ 3% 6 54 19.49 
3% < t ≤ 4% 7 53 19.98 
4% < t ≤ 5% 7 53 19.98 
5% < t ≤ 10% 10 50 20.98 
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CHAPTER 5 
DISCUSSION AND CONCLUSION 
Response Surface Methodology (RSM) is a “collection of statistical and mathematical 
techniques useful for developing, improving, and optimizing processes” (Myers et al., 2016). 
This method has been useful in different organization and industries, from agriculture to health 
care, in the design and improvement of new products (Myers et al., 2016). The aim of this 
project was to use these methods to optimize combination drug therapy among hypertensive 
patients, while taking into consideration common side effects that occur among those being 
treated with these drugs.  
This study focused on two drugs commonly combined for the treatment of hypertensive I 
and II patients. Design and data parameters were similar to the study conducted by a 
pharmaceutical industry: Factorial Design Study for the Treatment of Hypertension (Clinical trial 
identification number: NCT00281580). Results from the first stage of this study revealed the 
optimum point of efficacious response. The optimum change in blood pressure from baseline 
diastolic blood pressure to end – of – treatment blood pressure, after 8 weeks, was estimated as 
21mmhg. This point of optimal response was associated with a stationary point of 10mg of Drug 
A and 40mg of Drug B.  
The other part of the study was to formulate a clinically reasonable safety constraint to be 
added to the model. The objective was to optimize the combination drug therapy while 
constraining for the probability of edema incidence. The point of minimum risk occurs when 
dose of Drug A is 2.5mg and dose of Drug B is 20mg (if considering the combination).  While 
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this might have occurred for the adverse effect Edema, it is important to note that it might not 
apply to other adverse effects.  
The optimal responses for the unconstrained and the constrained models should not be 
taken and interpreted as exact, as it could lead to some misleading conclusions. The stationary 
point only gives a suggestion as to the region of optimal response. Standard errors and 
confidence regions around the stationary point should also be taken into consideration.  
In clinical practice, the clinician is mostly concerned about the efficacy of the drug or 
therapy, but it also advisable not to ignore the possibility of adverse effects (Myers et al., 2016). 
Monotherapy or combined therapy in hypertension are done to suite the physical and biological 
qualities of patients. Different patients react to drugs differently. Most often, it is the duty of the 
physician to advise on the best drugs or therapy for a patient. The response to drug or therapy for 
an individual depends on several factors such as age, sex, race, genetics and hereditary factors. 
This study was not able to consider these factors in the analysis, which is one of its limitations. 
Also, though Response Surface Methodology (RSM) have been applied in many disciplines, 
constraint optimization methods are still very novel in its application to health and clinical 
therapy. Application of this method will require formulation of constraints that suites the disease 
of interest, and that is also clinically explainable.  
Public Health Implications 
“Patient safety is an essential principle of healthcare” (Al-Saadoon, 2015).  The 
effectiveness of drugs and the occurrence of unexpected, unwanted and unpredictable adverse 
drug reactions continue to be a serious public health problem. These have been noted to be one 
of the major causes of hospitalizations in many countries of the world (Kollek, van Aken, 
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Feuerstein, & Schmedders, 2006). Adverse effects could be associated with any phase of 
healthcare; Practice, Products, Procedures or Provision (Al-Saadoon, 2015). Several measures, 
such as pharmacogenetics and pharmacovigilance are being put in place, to ensure drugs have 
required efficacy with less occurrence of adverse effects. This is to ensure that major public 
health programs are supported through “providing reliable, balanced information for the effective 
assessment of the risk-benefit profile of medicines” (World Health Organization, 2019a). The 
aims of the WHO Pharmacovigilance are to: (i) improve patient care and safety in relation to the 
use of medicines and all medical and paramedical interventions; (ii) improve public health and 
safety in relation to the use of medicines; (iii) detect problems related to the use of medicines and 
communicate the findings in a timely manner; (iv) contribute to the assessment of benefit, harm, 
effectiveness and risk of medicines, leading to the prevention of harm and maximization of 
benefit; (v) encourage the safe, rational and more effective (including cost-effective) use of 
medicines; and (vi) promote understanding, education and clinical training in pharmacovigilance 
and its effective communication to the public (World Health Organization, 2019a).  
In the United states, the Center for Drug Evaluation and Research (CDER),  branch of the 
Food and Drug administration (FDA) “performs an essential public health task by making sure 
that safe and effective drugs are available to improve the health of the people in the United 
States” (Food and Drug Administration, 2019). CDER ensure that drugs information, safety and 
availability are regularly updated. The Drug safety communications provides relevant and 
updated information to the public in the English and Spanish Language. Every year, there is a 
new and updated release of information. CDER also controls the drug development and review 
process, regulatory science research and education, drug approvals and databases, and guidance, 
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compliance/regulatory information. They also prepare and respond to natural disasters, nuclear 
and chemical attacks (Food and Drug Administration, 2019). 
Policy Implementation 
The World Health Organization has established policies to control the safety and 
utilization of drugs worldwide. One of those initiations is the Quality Assurance and Safety of 
Medicines (QSM). The QSM issues guidelines as regards to the nomenclature, quality norms and 
standards, drug safety and regulatory information exchange, prequalification of priority 
medicines, and harmonization of medicine regulations (World Health Organization, 2019c). The 
WHO also established the Collaborating Center for International Drug Monitoring to help 
maintain database for reports of adverse reactions from member states (Al-Saadoon, 2015). In 
the United States, the FDA also acts a governing and regulatory body. They provide the 
guidance, compliance and regulatory information to ensure proper control of production and use 
of drugs and devices. To provide evidence of effectiveness of new drugs and devices, the US. 
Department of Health and Human Services, Food and Drug Administration, Center for Drug 
Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) 
issued a document to guide the industry in the production of new drugs, biologics or devices. In 
April 2019, the FDA also issued a compliance policy for combination product post-marketing 
safety.  
Suggestions for Future Research 
Constrained optimization methods have had very few applications in the health sector, 
and in drug therapy. Further studies are advised on other disease of interest, and more simpler 
measures will help to enhance improvement in this area. There are also few software supports, 
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especially in the multi-response situations. There is need for more development of reliable 
software support systems to implement methodologies and perform analysis. There should also 
be modifications in the multi-response technique to allow the inclusion of block effect in the 
model (Khuri, 2017). There is need for research and development for non-parametric techniques; 
model-free techniques (Khuri, 2017).  
The methods used in this research were applied to a generated data set to mimic data from a 
Phase III clinical trial of doses of two drugs used in combination to treat hypertensive I and II 
patients. In practice, a Phase II clinical trial would be conducted, and the methods used to 
estimate doses of the two drugs that would be predicted to provide maximum efficacy while 
constraining important adverse events to an acceptable clinical level. These doses would then be 
used in a Phase III clinical trial for confirmation. 
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